Literature DB >> 25854372

IL-35 over-expression is associated with genesis of gastric cancer.

Yong-Gang Fan1, Jing-Ming Zhai, Wei Wang, Bing Feng, Guo-Liang Yao, Yan-Hui An, Chao Zeng.   

Abstract

Overexpression of interleukin (IL)-35 has been found in a variety of malignancies, but the expression status in gastric cancer has yet to be elucidated clearly. In the present study, positive expression of EBI3 and p35 was 63.3% and 70.0% of cases, respectively. EBI3 expression was strongly related with larger tumor size and invasion depth (P<0.05). Similarly, expression of p35 was also correlated with larger tumor size (P<0.05). These results indicate that IL-35 might be involved in growth of gastric cancer. Interestingly, EBI3 and p35 expressions were positive correlated with Ki-67 expression. Moreover, EBI3 immunoreactivity was associated with Bcl-2 staining. Our data suggest IL-35 is correlated with genesis of gastric cancer by regulating growth and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25854372     DOI: 10.7314/apjcp.2015.16.7.2845

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  18 in total

1.  Genetic polymorphism in association with susceptibility to tuberculosis: a study in a Pakistani population.

Authors:  AsmaGul Naz; Muhammad Assad Aslam; Abrar Ul Haq Khan; Sumaira Rasul; Hamid Manzoor; Rehana Iqbal; Ahmed Shehzad; Muhammad Ali
Journal:  Braz J Microbiol       Date:  2019-02-25       Impact factor: 2.476

2.  Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients.

Authors:  Tullia C Bruno; Peggy J Ebner; Brandon L Moore; Olivia G Squalls; Katherine A Waugh; Evgeniy B Eruslanov; Sunil Singhal; John D Mitchell; Wilbur A Franklin; Daniel T Merrick; Martin D McCarter; Brent E Palmer; Jeffrey A Kern; Jill E Slansky
Journal:  Cancer Immunol Res       Date:  2017-08-28       Impact factor: 11.151

3.  IL-35 expression is increased in laryngeal squamous cell carcinoma and in the peripheral blood of patients.

Authors:  Wei Wu; Hua Jiang; Ying Li; Mao-Xiao Yan
Journal:  Oncol Lett       Date:  2017-03-14       Impact factor: 2.967

4.  Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer.

Authors:  Guanghui Chen; Yanfang Liang; Xin Guan; Hui Chen; Qiankun Liu; Bihua Lin; Can Chen; Mingyuan Huang; Jianan Chen; Weiquan Wu; Yi Liang; Keyuan Zhou; Jincheng Zeng
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

5.  IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression.

Authors:  Jun Long; Hongyan Guo; Shichang Cui; Haiyan Zhang; Xinmin Liu; Danning Li; Zimeng Han; Linfeng Xi; Wenyi Kou; Jiangnan Xu; Tao-Sheng Li; Yaozhong Ding
Journal:  Oncotarget       Date:  2016-07-19

6.  IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease.

Authors:  Ivy M Dambuza; Chang He; Jin Kyeong Choi; Cheng-Rong Yu; Renxi Wang; Mary J Mattapallil; Paul T Wingfield; Rachel R Caspi; Charles E Egwuagu
Journal:  Nat Commun       Date:  2017-09-28       Impact factor: 14.919

7.  Interleukin-35 expression is associated with colon cancer progression.

Authors:  Jian Zhang; Tao Mao; Shuyun Wang; Dongsheng Wang; Zhaojian Niu; Zhenqing Sun; Jianli Zhang
Journal:  Oncotarget       Date:  2017-05-10

Review 8.  Positive and negative functions of B lymphocytes in tumors.

Authors:  Meng Shen; Qian Sun; Jian Wang; Wei Pan; Xiubao Ren
Journal:  Oncotarget       Date:  2016-08-23

9.  Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection.

Authors:  Qingjie Song; Xi Chen; Weidong Hu; Guanglin Mei; Xiaobing Yang; Han Wu
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

Review 10.  [Current Research of the Roles of IL-35 in Tumor Progression].

Authors:  Chongbiao Huang; Ye Tian; Yan Cui; Jie Xu; Liang Xin; Xueling Yang; Daliang Qi
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.